Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Index by author

July 01, 1995; Volume 23,Issue 7
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

A

  1. Acheampong, A A

    1. You have access
      Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
      A A Acheampong, M Shackleton and D D Tang-Liu
      Drug Metabolism and Disposition July 1995, 23 (7) 708-712;
  2. Agen, C

    1. You have access
      Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;

B

  1. Balani, S K

    1. You have access
      Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;
  2. Bocci, G

    1. You have access
      Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;
  3. Born, S L

    1. You have access
      Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression, and site-directed mutagenesis.
      S L Born, G H John, G R Harlow and J R Halpert
      Drug Metabolism and Disposition July 1995, 23 (7) 702-707;
  4. Bowers, G D

    1. You have access
      Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;
  5. Bracken, W

    1. You have access
      Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;
  6. Bullock, P

    1. You have access
      Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;
  7. Buters, J T

    1. You have access
      cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
      J T Buters, M Shou, J P Hardwick, K R Korzekwa and F J Gonzalez
      Drug Metabolism and Disposition July 1995, 23 (7) 696-701;

C

  1. Cannell, R J

    1. You have access
      Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;
  2. Carlson, T J

    1. You have access
      Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;
  3. Carrel, B K

    1. You have access
      Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;
  4. Castagnoli, N

    1. You have access
      Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;
  5. Chen, I W

    1. You have access
      pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
      J H Lin, I W Chen, K J Vastag and D Ostovic
      Drug Metabolism and Disposition July 1995, 23 (7) 730-735;
  6. Cribb, A

    1. You have access
      Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6.
      A Cribb, C Nuss and R Wang
      Drug Metabolism and Disposition July 1995, 23 (7) 671-675;

D

  1. Danesi, R

    1. You have access
      Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;
  2. Dawson, M J

    1. You have access
      Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;
  3. Del Tacca, M

    1. You have access
      Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;
  4. Di Paolo, A

    1. You have access
      Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;
  5. Draper, A

    1. You have access
      Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;
  6. Dwyer, L M

    1. You have access
      Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;

E

  1. Eddershaw, P J

    1. You have access
      Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;
  2. Elder, C A

    1. You have access
      Interspecies scaling of a thienodiazepine platelet-activating factor receptor antagonist.
      C A Elder and M W Modi
      Drug Metabolism and Disposition July 1995, 23 (7) 776-778;
  3. Ellis, J D

    1. You have access
      Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;
  4. Estabrook, R W

    1. You have access
      In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

F

  1. Ferrero, J L

    1. You have access
      In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

G

  1. Gonzalez, F J

    1. You have access
      cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
      J T Buters, M Shou, J P Hardwick, K R Korzekwa and F J Gonzalez
      Drug Metabolism and Disposition July 1995, 23 (7) 696-701;

H

  1. Halpert, J R

    1. You have access
      Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression, and site-directed mutagenesis.
      S L Born, G H John, G R Harlow and J R Halpert
      Drug Metabolism and Disposition July 1995, 23 (7) 702-707;
  2. Hardwick, J P

    1. You have access
      cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
      J T Buters, M Shou, J P Hardwick, K R Korzekwa and F J Gonzalez
      Drug Metabolism and Disposition July 1995, 23 (7) 696-701;
  3. Harlow, G R

    1. You have access
      Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression, and site-directed mutagenesis.
      S L Born, G H John, G R Harlow and J R Halpert
      Drug Metabolism and Disposition July 1995, 23 (7) 702-707;
  4. Ho, J

    1. You have access
      Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;

I

  1. Iga, T

    1. You have access
      Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
      M Katashima, K Yamamoto, M Sugiura, Y Sawada and T Iga
      Drug Metabolism and Disposition July 1995, 23 (7) 718-723;
  2. Innocenti, F

    1. You have access
      Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;
  3. Iyer, K R

    1. You have access
      Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;

J

  1. John, G H

    1. You have access
      Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression, and site-directed mutagenesis.
      S L Born, G H John, G R Harlow and J R Halpert
      Drug Metabolism and Disposition July 1995, 23 (7) 702-707;
  2. Jones, J P

    1. You have access
      Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;

K

  1. Katashima, M

    1. You have access
      Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
      M Katashima, K Yamamoto, M Sugiura, Y Sawada and T Iga
      Drug Metabolism and Disposition July 1995, 23 (7) 718-723;
  2. Kauffman, L R

    1. You have access
      Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;
  3. Knaggs, A R

    1. You have access
      Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;
  4. Kocarek, T A

    1. You have access
      Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes.
      R C Zangar, K J Woodcroft, T A Kocarek and R F Novak
      Drug Metabolism and Disposition July 1995, 23 (7) 681-687;
  5. Korzekwa, K R

    1. You have access
      cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
      J T Buters, M Shou, J P Hardwick, K R Korzekwa and F J Gonzalez
      Drug Metabolism and Disposition July 1995, 23 (7) 696-701;
  6. Kukulka, M J

    1. You have access
      In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;
  7. Kuo, B S

    1. You have access
      Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;

L

  1. Lee, R D

    1. You have access
      In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;
  2. Lin, J H

    1. You have access
      pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
      J H Lin, I W Chen, K J Vastag and D Ostovic
      Drug Metabolism and Disposition July 1995, 23 (7) 730-735;

M

  1. Malspeis, L

    1. You have access
      Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog.
      L R Phillips, L Malspeis and J G Supko
      Drug Metabolism and Disposition July 1995, 23 (7) 676-680;
  2. Manchee, G R

    1. You have access
      Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;
  3. Mathews, B S

    1. You have access
      Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;
  4. Modi, M W

    1. You have access
      Interspecies scaling of a thienodiazepine platelet-activating factor receptor antagonist.
      C A Elder and M W Modi
      Drug Metabolism and Disposition July 1995, 23 (7) 776-778;
  5. Mulford, D J

    1. You have access
      In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

N

  1. Nardini, D

    1. You have access
      Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;
  2. Novak, R F

    1. You have access
      Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes.
      R C Zangar, K J Woodcroft, T A Kocarek and R F Novak
      Drug Metabolism and Disposition July 1995, 23 (7) 681-687;
  3. Nuss, C

    1. You have access
      Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6.
      A Cribb, C Nuss and R Wang
      Drug Metabolism and Disposition July 1995, 23 (7) 671-675;

O

  1. Ostovic, D

    1. You have access
      pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
      J H Lin, I W Chen, K J Vastag and D Ostovic
      Drug Metabolism and Disposition July 1995, 23 (7) 730-735;

P

  1. Parkinson, A

    1. You have access
      Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;
  2. Pearce, R

    1. You have access
      Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;
  3. Peterson, L

    1. You have access
      Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;
  4. Phillips, L R

    1. You have access
      Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog.
      L R Phillips, L Malspeis and J G Supko
      Drug Metabolism and Disposition July 1995, 23 (7) 676-680;
  5. Pitzenberger, S M

    1. You have access
      Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;
  6. Podval, J

    1. You have access
      Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;
  7. Prueksaritanont, T

    1. You have access
      Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;

R

  1. Rodrigues, A D

    1. You have access
      In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;
  2. Rose, J Q

    1. You have access
      Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;

S

  1. Sawada, Y

    1. You have access
      Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
      M Katashima, K Yamamoto, M Sugiura, Y Sawada and T Iga
      Drug Metabolism and Disposition July 1995, 23 (7) 718-723;
  2. Shackleton, M

    1. You have access
      Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
      A A Acheampong, M Shackleton and D D Tang-Liu
      Drug Metabolism and Disposition July 1995, 23 (7) 708-712;
  3. Shet, M S

    1. You have access
      In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;
  4. Shou, M

    1. You have access
      cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
      J T Buters, M Shou, J P Hardwick, K R Korzekwa and F J Gonzalez
      Drug Metabolism and Disposition July 1995, 23 (7) 696-701;
  5. Sidebottom, P J

    1. You have access
      Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;
  6. Stuhler, J D

    1. You have access
      Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;
  7. Sugiura, M

    1. You have access
      Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
      M Katashima, K Yamamoto, M Sugiura, Y Sawada and T Iga
      Drug Metabolism and Disposition July 1995, 23 (7) 718-723;
  8. Supko, J G

    1. You have access
      Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog.
      L R Phillips, L Malspeis and J G Supko
      Drug Metabolism and Disposition July 1995, 23 (7) 676-680;
  9. Surber, B W

    1. You have access
      In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;
  10. Sutherland, D R

    1. You have access
      Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;

T

  1. Tang-Liu, D D

    1. You have access
      Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
      A A Acheampong, M Shackleton and D D Tang-Liu
      Drug Metabolism and Disposition July 1995, 23 (7) 708-712;
  2. Theoharides, A D

    1. You have access
      Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;
  3. Thomas, P

    1. You have access
      Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;
  4. Thomas, S B

    1. You have access
      In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;
  5. Trager, W F

    1. You have access
      Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;

V

  1. Varga, S L

    1. You have access
      Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;
  2. Vastag, K J

    1. You have access
      pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
      J H Lin, I W Chen, K J Vastag and D Ostovic
      Drug Metabolism and Disposition July 1995, 23 (7) 730-735;
  3. Veltman, J

    1. You have access
      Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;

W

  1. Wang, R

    1. You have access
      Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6.
      A Cribb, C Nuss and R Wang
      Drug Metabolism and Disposition July 1995, 23 (7) 671-675;
  2. Waterhouse, I

    1. You have access
      Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;
  3. Woodcroft, K J

    1. You have access
      Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes.
      R C Zangar, K J Woodcroft, T A Kocarek and R F Novak
      Drug Metabolism and Disposition July 1995, 23 (7) 681-687;

Y

  1. Yamamoto, K

    1. You have access
      Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
      M Katashima, K Yamamoto, M Sugiura, Y Sawada and T Iga
      Drug Metabolism and Disposition July 1995, 23 (7) 718-723;

Z

  1. Zangar, R C

    1. You have access
      Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes.
      R C Zangar, K J Woodcroft, T A Kocarek and R F Novak
      Drug Metabolism and Disposition July 1995, 23 (7) 681-687;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 23, Issue 7
1 Jul 1995
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics